84545-14-2

Usage

Uses

Used in Organic Synthesis:
Benzamide, 4-(chloromethyl)(9CI) is used as a starting material in organic synthesis for the production of other organic compounds. Its unique structure allows for various chemical reactions, making it a valuable component in the synthesis of a wide range of organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, Benzamide, 4-(chloromethyl)(9CI) is used as an intermediate in the development of new drugs. Its chemical properties and reactivity make it a promising candidate for the synthesis of pharmaceutical compounds with potential therapeutic applications.
Used in Chemical Product Manufacturing:
Benzamide, 4-(chloromethyl)(9CI) is utilized as an intermediate in the manufacturing of various chemical products. Its versatility in chemical reactions contributes to the production of a diverse range of chemical products with different applications.
Used in Medicinal Chemistry:
Benzamide, 4-(chloromethyl)(9CI) may have potential applications in the field of medicinal chemistry for the development of new drugs. Its unique structure and reactivity can be leveraged to design and synthesize novel drug candidates with potential therapeutic benefits.
Used in Research and Development:
In research and development, Benzamide, 4-(chloromethyl)(9CI) is used to explore its potential applications and properties. Scientists and researchers investigate its chemical behavior, reactivity, and interactions with other compounds to better understand its potential uses and limitations in various industries.

InChI:InChI=1/C8H8ClNO/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4H,5H2,(H2,10,11)

Upstream product

• 551-93-9 2-aminoacetophenone 
• 552-89-6 2-nitro-benzaldehyde 
• 1603-91-4 4-methylthiazol-2-ylamine 
• 1642-81-5 p-(chloromethyl)benzoic acid 
• 876-08-4 p-(chloromethyl)benzoyl chloride 

Downstream Products

• 1642-81-5 p-(chloromethyl)benzoic acid 
• 84545-15-3 4-[3-nitropyrazol-1-ylmethyl]benzamide 
• 864528-53-0 4-(azidomethyl)benzamide 
• 6051-41-8 4-formylbenzamide 
• 1421044-91-8 4-((4-(6-(mesityloxy)-3-nitropyridin-2-yl-amino)piperidin-1-yl)methyl)benzamide 
• 1421044-99-6 4-((4-(6-(4-cyano-2,6-dimethylphenoxy)-3-nitropyridin-2-yl-amino)piperidin-1-yl)methyl)benzamide 
• 1421045-10-4 4-((4-(6-(mesitylamino)-3-nitropyridin-2-yl-amino)piperidin-1-yl)methyl)benzamide 
• 1421045-03-5 4-((4-(3-amino-6-(4-cyano-2,6-dimethylphenoxy)pyridin-2-ylamino)piperidin-1-yl)methyl)benzamide 
• 1421044-95-2 4-((4-(3-amino-6-(mesityloxy)pyridin-2-ylamino)piperidin-1-yl)methyl)benzamide 
• 1381770-31-5 4-((4-(4-amino-6-(mesitylamino)-1,3,5-triazin-2-ylamino)piperidin-1-yl)methyl)benzamide 
• 1381770-44-0 4-((4-(4-(mesitylamino)-6-methoxy-1,3,5-triazin-2-ylamino)piperidin-1-yl)methyl)benzamide 
• 1381770-39-3 4-((4-(4-(mesitylamino)-6-(methylamino)-1,3,5-triazin-2-ylamino)piperidin-1-yl)methyl)benzamide 
• 1240518-29-9 4-{[3-amino-4-(methyloxy)-1H-indazol-1-yl]methyl}benzamide 
• 911407-64-2 4-[3-(3,4-dichloro-benzyl)-6-methylsulfanyl-2,4-dioxo-3,4-dihydro-2H-[1,3,5]triazin-1-ylmethyl]-benzamide 

Relevant academic research and scientific papers

Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity

SCD1 is a rate-limiting enzyme in the conversion of saturated fatty acids to monounsaturated fatty acids. SCD1 inhibitors have potential effects on obesity, diabetes, acne, and cancer, but the adverse effects associated with SCD1 inhibition in the skin and eyelids are impediments to clinical development. To avoid mechanism-based adverse effects, we explored the compounds that selectively inhibit SCD1 in the liver in an ex vivo assay. Starting from a systemically active lead compound, we focused on the physicochemical properties tPSA and cLogP to minimize exposure in the off-target tissues. This effort led to the discovery of thiazole-4-acetic acid analog 48 as a potent and liver-selective SCD1 inhibitor. Compound 48 exhibited significant effects in rodent models of diabetes, hepatic steatosis, and obesity, with sufficient safety margins in a rat toxicology study with repeated dosing.

Acid-base profiling of imatinib (Gleevec) and its fragments

The site-specific basicities of imatinib (Gleevec, a new signal transduction inhibitor drug of chronic myeloid leukemia) and two of its fragment compounds were quantitated in terms of protonation macroconstants, microconstants, and group constants by NMR-pH and pH-potentiometric titrations. Sequential protonation of imatinib follows the N34, N11, N31, N13 order, in which N11 and N31 show commensurable basicity, but negligible intramolecular interaction. Fragment compounds include two "halves" of imatinib, and their moiety-specific basicities confirm the NMR-based protonation sequence of the parent compound. NMR-pH profiles, macro- and/or microscopic protonation schemes, and species-specific distribution diagrams are presented. On the basis of these data, imatinib is shown to be predominantly neutral, monocationic, and tricationic at intestinal, blood, and gastric pH, respectively. The molecular hypotheses on imatinib binding to the Bcr-Abl oncogene fusion protein are interpreted at the site-specific level in view of the moiety basicities of imatinib.

PROCESS FOR PREPARATION OF BENZYLPIPERIDINE COMPOUNDS

According to the process as shown in the following scheme having a step for reacting Compound (I) with Compound (II) to produce Compound (III), benzylpiperidine compounds useful as synthesis starting materials of pharmaceutical agents, agricultural chemicals and the like can be produced conveniently by a short step: wherein R1 is a hydrogen atom or an amino-protecting group, R2 is a hydrogen atom, a hydrocarbon group optionally having substituents, an alkoxy group optionally having substituents or a heterocyclic group optionally having substituents, and R3 is a lower alkyl group.

Nonpeptide agonists and antagonists of vasopressin receptors

The disclosed invention is a composition agonists and/or antagonists of V2, V1a or both receptors, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.